Novavax Stock Price Expected to Rise, Analyst Says

HC Wainwright raises price target on Novavax shares

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Research analysts at HC Wainwright have raised their price target on Novavax (NASDAQ:NVAX) stock from $11.00 to $16.00 and maintained a "buy" rating on the biopharmaceutical company's shares. The new price target suggests a potential upside of 42.98% from the company's previous closing price.

Why it matters

Novavax has faced some challenges in recent years, including concerns about its financial stability and the performance of its COVID-19 vaccine. However, this price target increase from a prominent analyst suggests growing optimism about the company's prospects and the potential for its stock to rise in value.

The details

In a research note issued on Friday, the analysts at HC Wainwright cited Novavax's recent financial results and progress on its vaccine development as reasons for the more bullish outlook. The company reported better-than-expected fourth-quarter revenue and a surprise quarterly profit, which helped lift investor confidence.

  • Novavax reported its Q4 2025 financial results on February 26, 2026.
  • HC Wainwright issued its updated price target and rating on Novavax on February 27, 2026.

The players

Novavax

A clinical-stage biotechnology company headquartered in Gaithersburg, Maryland that specializes in the discovery, development, and commercialization of next-generation vaccines to prevent serious infectious diseases.

HC Wainwright

A research and investment banking firm that provides equity research coverage on Novavax.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This price target increase from a respected analyst suggests growing optimism about Novavax's prospects, despite the company's past challenges. Investors will be closely watching to see if the company can continue to execute on its vaccine development and commercialization plans in order to drive further stock price appreciation.